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Abstract 
 
Aims 
Creatine buffers cellular ATP via the creatine kinase reaction. Creatine levels are reduced in heart 
failure, but their contribution to pathophysiology is unclear. Arginine:glycine amidinotransferase 
(AGAT) in the kidney catalyses both the first step in creatine biosynthesis as well as homoarginine 
synthesis. AGAT-/- mice fed a creatine-free diet have a whole body creatine-deficiency. We 
hypothesised that AGAT-/- mice would develop cardiac dysfunction and rescue by dietary creatine 
would imply causality.  
Methods and results 
Withdrawal of dietary creatine in AGAT-/- mice provided an estimate of myocardial creatine efflux 
of ~2.7%/day, however, in vivo cardiac function was maintained despite low levels of myocardial 
creatine. Using AGAT-/- mice naïve to dietary creatine we confirmed absence of phosphocreatine 
in the heart, but crucially, ATP levels were unchanged. Potential compensatory adaptations were 
absent, AMPK was not activated and respiration in isolated mitochondria was normal. AGAT-/- 
mice had rescuable changes in body water and organ weights suggesting a role for creatine as a 
compatible osmolyte. Creatine-naïve AGAT-/- mice had haemodynamic impairment with low LV 
systolic pressure and reduced inotropy, lusitropy and contractile reserve. Creatine 
supplementation only corrected systolic pressure despite normalisation of myocardial creatine. 
AGAT-/- mice had low plasma homoarginine and supplementation completely rescued all other 
haemodynamic parameters. Contractile dysfunction in AGAT-/- was confirmed in Langendorff 
perfused hearts and in creatine-replete isolated cardiomyocytes, indicating that homoarginine is 
necessary for normal cardiac function.  
Conclusions 
Our findings argue against low myocardial creatine per se as a major contributor to cardiac 
dysfunction. Conversely, we show that homoarginine deficiency can impair cardiac function, 
which may explain why low homoarginine is an independent risk factor for multiple cardiovascular 
diseases. 
 
 
Keywords 
Creatine kinase; cardiac energetics; contractile function; homoarginine, AGAT 
 
 
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvx242/4721788
by University of Leeds - Librarian user
on 09 January 2018
CVR-2017-539R2 
 
3 
 
1. Introduction 
The heart has a constant requirement for large amounts of energy in the form of ATP and must 
maintain the ability to instantly respond to elevated workloads. Despite this, intracellular ATP 
levels do not change in the healthy heart, which implies a tight match between ATP demand and 
supply via glycolysis and oxidative phosphorylation.1 The creatine kinase (CK) phosphagen 
system is considered key to this by buffering ATP levels via rapid and reversible transfer of the 
phosphoryl group of ATP onto creatine (Cr) to form phosphocreatine (PCr)2: Cr + ATP ↔ PCr + 
ADP + H+. 
In animal models and patients with heart failure, a decrease in total creatine levels and CK 
enzymatic activity is consistently observed, regardless of aetiology.3 For example, in patients with 
dilated cardiomyopathy, the ratio of PCr/ATP is reduced at an early stage of pathology and 
correlates with ejection fraction and survival.4 However, despite decades of research, the exact 
contribution (i.e. cause or effect) of reduced creatine to cardiac pathophysiology remains 
controversial.  
Creatine is not synthesised in the cardiomyocyte, but must either be obtained from dietary sources 
or biosynthesized from arginine and glycine in a two-step reaction. The first, catalysed by 
arginine:glycine amidinotransferase (AGAT) predominantly in the kidney, produces 
guanidinoacetate, which is subsequently methylated by guanidinoacetate N-methyltransferase 
(GAMT), mostly in the liver, to form creatine. Creatine is subsequently absorbed by 
cardiomyocytes against a large concentration gradient via a specific creatine transporter 
(SLC6A8).2 
Previous approaches have studied the effects of creatine depletion using creatine analogues such 
as guanidinopropionic acid (β-GPA), which competes with creatine for cellular uptake, but is a 
poor substrate for CK.2 Typically, baseline dysfunction is mild or absent, except at high 
workloads.5-10 The GAMT-/- model, too, is in agreement with this general pattern, showing only a 
small reduction in left ventricular (LV) systolic pressure at baseline, but with impaired contractile 
reserve.11 The physiological relevance of this impairment is unclear since GAMT-/- mice ran just 
as far and as fast as controls under voluntary and forced running protocols. Furthermore, following 
experimental myocardial infarction, cardiac function and remodelling were not altered in creatine-
deficient GAMT-/- mice.12 
Both these approaches have major limitations. On the one hand, depletion of creatine by β-GPA 
is very slow, and there is always residual creatine (typically 10-50%). On the other hand, GAMT-
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/- mice receiving a creatine-free diet are completely deficient in creatine, but accumulate millimolar 
concentrations of guanidinoacetate, which (as with β-GPA) can potentially compensate the 
creatine deficiency by participating in the CK reaction, albeit at a much reduced velocity.13 There 
is evidence that high levels of guanidinoacetate and β-GPA can be toxic or have off-target effects 
(e.g., inhibition of the Na+/K+ pump 14), and it is therefore difficult to know with any certainty 
whether the observed effects are due to true creatine deficiency. For these reasons, the AGAT-/- 
mouse has been keenly awaited in this field as a “pure” model of creatine deficiency that might 
yield definitive answers. This is exemplified by the skeletal muscle phenotype, which is much 
more severe in AGAT-/- than in GAMT-/- mice and was completely reversed by creatine 
supplementation.13, 15, 16 
It is known that the AGAT enzyme is also the principle source of homoarginine (HA) in both 
humans and mice.17, 18 HA is a cationic amino acid structurally similar to arginine, but with an 
additional carbon in the alkyl chain.19 It has no established metabolic role and, until recently, was 
assumed to be an incidental by-product of the homologous urea cycle.20 Notably, low plasma HA 
levels have been associated with increased cardiovascular risk.21  
Here, we present the first description of the cardiac phenotype in AGAT-/- mice. Withdrawal of 
dietary creatine allowed us to estimate the rate of myocardial creatine efflux. We confirm that 
AGAT-/- mice fed a creatine-free diet are devoid of creatine and PCr in the heart, and determined 
the effect on LV structure and function using MRI. Non-invasive magnetic resonance relaxometry 
allowed us to analyse body composition in detail and to demonstrate rescue by creatine 
supplementation. Finally, LV haemodynamic function was assessed under low-creatine 
conditions in the absence of potentially confounding guanidino compounds as well as after 
creatine and HA replenishment.. 
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2. Methods 
Detailed methods can be found in the supplementary material. 
2.1 Animals and ethical statement 
This investigation was approved by the Committee for Animal Care and Ethical Review at the 
University of Oxford and conforms to the UK Animals (Scientific Procedures) Act, 1986, 
incorporating Directive 2010/63/EU of the European Parliament. Arginine:glycine 
amidinotransferase knockout mice (AGAT-/-) have a homozygous knockout of the Gatmtm1.1Isb 
allele created by homologous recombination.22 All procedures used mice aged 4-7 months on a 
pure C57BL/6J genetic background (backcrossed for >10 generations). Mice were housed in 
specific pathogen-free cages and maintained on a 12-h/12-h light-dark cycle under conditions of 
controlled temperature (20-22°C) and humidity. Water and chow were available ad libitum. 
 
2.2 Dietary manipulation of creatine and homoarginine 
Since AGAT-/- mice are unable to biosynthesize creatine, the myocardial creatine levels are 
dependent on dietary intake. Two types of study were performed based on the following diets and 
summarized in Figure 1: A) Creatine withdrawal study: mice were bred and weaned onto a chow 
supplemented with creatine monohydrate (0.5% w/w), then switched to a standard creatine-free 
chow at 4-5 months. B) Creatine-naïve mice and dietary rescue: AGAT-/- mice fed a creatine-free 
chow throughout development are termed ‘creatine-naïve’ and have whole-body creatine 
deficiency. Dietary creatine was introduced in adulthood by switching to a standard diet with 0.5% 
w/w creatine for either 1 week or 7 weeks. L-homoarginine hydrochloride (HA, Sigma-Aldrich, UK) 
was added to the drinking water at a concentration of 14mg/L for 10 days.18, 23 
 
2.3 In vivo cardiac phenotyping 
All in vivo magnetic resonance experiments were carried out under isoflurane anaesthesia on a 
9.4T- (400 MHz) MR system (Agilent Technologies) and using a quadrature-driven birdcage 
resonator (Rapid Biomedical) for high-resolution Magnetic Resonance cine Imaging (cine MRI) 
and cardiac 1H-MRS. Haemodynamic measurements in the left ventricle were made under 
isoflurane anaesthesia using a 1F-miro-tip catheter (Millar, Texas, USA) as previously 
described.12 Dobutamine was infused at 16ng/g BW/min via the jugular vein as a measure of 
contractile reserve. Mice were killed by cervical dislocation at the end of the experiments and their 
organs removed, washed in heparinised saline, blotted, and weighed. 
 
2.4 Isolated perfused heart function 
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Creatine naïve AGAT-/- (n=8) and WT (n=7) mice were anaesthetised with sodium pentobarbital, 
hearts rapidly excised, cannulated and perfused in Langendorff constant pressure mode at 
80mmHg with oxygenated Krebs-Henseleit buffer at 37°C. LV function was assessed in 
spontaneously beating hearts using a water-filled intraventricular balloon with end-diastolic 
pressure set to 6.1 ± 0.7 mmHg. 
 
2.5 Isolated cardiomyocyte function 
LV cardiomyocytes were isolated via enzymatic dispersion from WT and AGAT-/- mice that had 
been fed a creatine containing diet throughout life. Cell shortening and re-lengthening velocity 
were measured under field-stimulation (3 Hz; 35 ± 1°C) using a video-edge detection system 
(IonOptix Corp). In a subset of cardiomyocytes, the [Ca2+]i transient was measured in fura-2 
loaded (5 µmol/L, Molecular Probes) myocytes.   
 
2.6 Biochemistry 
High-energy phosphates were measured in isolated perfused hearts by 31P-MRS as previously 
described.11 Plasma HA levels were quantified in mouse plasma using a stable isotope dilution 
assay for LC–MS/MS.24 Creatine and taurine levels were quantified by solution-state 1 H-NMR 
spectroscopy in LV tissue (~50 mg) from creatine-naïve mice (3 AGAT-/- and 3 WT, age-matched 
females, mean 30 weeks). Total citrate synthase, adenylate kinase (AK) activity, creatine kinase 
(CK) activity, and CK isoenzyme composition were measured in LV homogenates. 
 
2.7 Mitochondrial respiration 
Cardiac mitochondria were isolated from creatine-naïve AGAT-/- (n=8) and WT (n=7) and basal 
respiration assessed with a Clark-type electrode using the Mitocell S200A Micro Respiratory 
System (Strathkelvin Instruments, Motherwell, UK) using glutamate (5mM), malate (2.5mM), and 
Na+-pyruvate (5mM) as substrates. 
 
2.8 Cardiomyocyte cross-sectional area 
Hearts from creatine-naïve mice were fixed in 10% buffered formalin, dehydrated, and embedded 
in paraffin. Eight-micron-thick sections were stained with Masson’s trichrome and measurements 
were made on ~150-200 myocytes per animal. 
 
2.9 Body composition 
Body composition was measured in conscious mice using an EchoMRI-100 quantitative magnetic 
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resonance whole body composition analyzer (Echo Medical Systems, Houston, USA). 
 
2.10 Data analysis 
Analysis of haemodynamics, MR data, single cell experiments and all biochemistry 
measurements were performed independently and analysed in a blinded fashion. Data are 
expressed as mean ± SD unless otherwise stated. The following statistical tests were used: paired 
two-tailed t-test for comparison of AGAT-/- before and after creatine withdrawal, unpaired two-
tailed t-test for comparison of AGAT-/- vs WT, Mann-Whitney U test for comparison of AGAT-/- vs 
WT in cases where normal distribution was violated, 1-way ANOVA for multiple group 
comparisons, and 2-way ANOVA to assess the effect of genotype and treatment on body 
composition and for comparison of the haemodynamic response to dobutamine. For all single cell 
variables, analysis was carried out in RStudio using a hierarchical statistical method.25 In cases 
where variables was non-normally distributed, data was logarithmically transformed prior to 
statistical analysis. Bonferroni’s correction for multiple comparisons was used throughout this 
study with a significance level of P<0.05. 
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3. Results 
A. Creatine withdrawal study: Since AGAT-/- mice are dependent on dietary creatine, we 
hypothesised that changing to a creatine-free diet in adulthood would lead to a gradual reduction 
in myocardial creatine levels to demonstrate whether low creatine, as observed in the failing heart, 
can cause cardiac dysfunction per se. Figure 1A shows a schematic of the experimental protocol. 
 
3.1 Dietary creatine withdrawal leads to myocardial creatine loss 
Myocardial creatine levels were measured non-invasively using 1H-MRS before and after dietary 
creatine withdrawal in 6 adult AGAT-/- mice. At day 0, myocardial creatine levels were similar to 
those of WT at 75 ± 10 nmol/mg protein (cf. 68 ± 5 for WT in Table) and were undetectable using 
1H-MRS by day 83 (Figure 2A-B). Creatine loss followed a clear exponential decay pattern with a 
calculated constant rate of 2.7 ± 0.4 % of the total creatine pool lost per day. However, residual 
creatine was detected by HPLC at day 91 (22.8 ± 2.5 nmol/mg protein), suggesting that part of 
the creatine pool may not have been visible on MR in vivo.  
 
3.2 Creatine withdrawal alters body weight but not cardiac function 
Body weight was stable until day 60 of creatine withdrawal, after which we observed gradual and 
persistent weight loss of ~0.5% of the initial body weight per day. After 91 days on a creatine-free 
diet, mice had lost 14% body weight (P<0.001), which required the termination of the experiment 
for animal welfare reasons (Figure 2C). Cine-MRI examination during the withdrawal period 
showed a commensurate reduction in LV mass, which was 8% lower by the final time point 
(P<0.01) (Figure 2D). During this period, there was no change in cardiac function assessed non-
invasively using cine-MRI, that is, ejection fraction and cardiac output remained stable 
(Supplementary Table S1). 
 
In vivo LV haemodynamic measurements were made at the final time point before and after 
maximal β-adrenergic stimulation with dobutamine (Figure 2E-H). There were no significant 
differences between AGAT-/- mice following creatine withdrawal and the control group of AGAT-/- 
mice fed creatine throughout the experiments. For example, left ventricular pressures, parameters 
of contraction (dP/dtmax), and relaxation (dP/dtmin) were all indistinguishable from Cr-fed AGAT-/- 
controls. Moreover, contractile reserve, the increase in function observed upon dobutamine 
stimulation, which is a sensitive marker for early cardiac dysfunction, was unaltered. Post-mortem 
data confirmed reduced LV mass and lung weights in mice withdrawn from Cr compared to the 
control group (Supplementary Table S1). 
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B. Creatine-naïve mice and dietary rescue: Since cardiac function was unaffected by dietary 
creatine withdrawal, we sought to study the extreme scenario of absolute creatine-deficiency, to 
determine whether complete absence of creatine causes cardiac dysfunction. For these 
experiments we used AGAT-/- mice from a colony that had always been maintained on a creatine-
free diet (i.e. creatine- naïve). To determine causality for the observed phenotypes we performed 
dietary rescue experiments as per the schematic in Figure 1B. 
 
3.3 Creatine-naïve AGAT-/- hearts are devoid of creatine 
Hearts were perfused in Langendorff mode for assessment of high-energy phosphates by 31P-
MRS. The complete absence of phosphocreatine (PCr) in AGAT-/- hearts (Figure 3A-B) was most 
striking and resulted in elevated inorganic phosphate, while ATP and intracellular pH remained at 
normal wild-type levels (Table). Total adenine nucleotides (i.e., AMP + ADP + ATP) were 
unchanged. Determination of total creatine by HPLC could not resolve a peak above background 
noise, and we thus confirmed, using solution state 1H-NMR, that creatine levels were negligible. 
The cellular osmolyte taurine was elevated by 24% in AGAT-/- hearts, which may partially 
compensate for the osmotic stress caused by creatine deficiency. 
 
3.4 Creatine-naïve hearts do not exhibit cardiac hypertrophy 
Whole-body creatine deficiency resulted in severely reduced body weight (52% lower), but with a 
disproportionate reduction in long bone length (tibial length 4% shorter), which complicated the 
interpretation of organ weights. For example, absolute LV weight was significantly lower in age-
matched AGAT-/- mice compared to WT, confirmed when normalised to tibial length, but is 
significantly higher than WT when normalised to body weight (Table). We therefore determined 
the gene expression of molecular markers of hypertrophy (i.e., ANP, BNP, β-MHC, α-SA), which 
were not consistently elevated in AGAT-/- hearts (one marker was elevated, another one was 
reduced, and two other markers were unchanged). Absence of a molecular programme of 
hypertrophy was confirmed at the cellular level by histology, with the myocyte cross-sectional 
area found to be unaltered (Table). 
 
3.5 Creatine-naïve hearts and markers of energy homeostasis 
We analysed the expression of key energy homeostasis enzymes for evidence of compensatory 
adaptation. The total absence of substrate resulted in a 2.1-fold up-regulation of creatine 
transporter gene expression (P=0.02), but the activity of creatine kinase (CK) and the distribution 
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of CK isoenzymes were unaltered (Figure 3C-D). Adenylate kinase may also play a phospho-
transfer role in the heart and can compensate for the loss of CK system function; however, AK 
activity was also unaltered in creatine-naïve AGAT-/- hearts (Figure 3E). Phosphorylation of AMP-
activated protein kinase (AMPK) is a common indicator of impaired energetic status, but AMPK 
was not activated in the AGAT-/- heart (Figure 3F). This was surprising since previous studies 
showed AMPK activation in skeletal muscle from AGAT-/- mice,22 and we therefore sought to 
confirm this as a positive control for our own assay. AMPK was indeed activated in skeletal muscle 
of our AGAT-/- mice (Figure 3F), indicating a divergence of the biochemical consequences of 
creatine depletion in cardiac as compared to skeletal myocytes. AMPK activation in AGAT-/- 
skeletal muscle stimulates the PGC1-α mitochondrial biogenesis pathway and thereby increases 
citrate synthase activity (a marker for mitochondrial volume).15 In agreement with the lack of 
AMPK activation in heart, we observed no change in citrate synthase activity in cardiac muscle of 
AGAT-/- (Figure 3G). Furthermore, there was no difference in baseline or ADP-stimulated 
respiration in mitochondria isolated from WT and AGAT-/- hearts (Figure 3H). 
 
3.6 Creatine-naïve mice have altered body composition 
Body composition measured non-invasively by MR relaxometry showed that AGAT-/- mice had 
significantly lower lean mass and markedly reduced body fat and water content (Figure 4A). The 
relationship between percentage fat and water was highly linear over a wide range of body 
weights26, as can be seen for WT mice in Figure 4B. For AGAT-/-, the slope was significantly 
altered (P<0.0001), suggesting a fundamental breakdown in this relationship. To establish the 
role of creatine on body composition, we supplemented the diet of AGAT-/- mice with 0.5% creatine 
monohydrate for 1 week, which is sufficient to normalise tissue levels (e.g., in myocardium [Cr] 
WT 74±3 vs AGAT-/- 70±2 nmol/mg protein). A 7-week creatine supplementation was also 
included to determine the long-term consequences. A further group consisted of AGAT-/- mice 
supplemented with 14 mg/L homoarginine added to the drinking water for 10 days in order to rule 
out a role for HA deficiency. After 1 week of creatine feeding, the linear relationship between body 
fat and water was abolished (slope=0), whereas the relationship was indistinguishable from WT 
by 7 weeks and unaffected by HA (Figure 4C). Body composition analysis before and after 
supplementation showed a rapid increase in lean mass and body water by 1 week (Figure 4F-G), 
which is consistent with creatine having both an ergogenic and osmotic role. A gain in fat mass 
was not observed until after 7 weeks (Figure 4E), which restored the fat-water relationship (Figure 
4C). These observations are likely to provide an explanation for the low post-mortem organ 
weights in AGAT-/- mice, which were rescued within one week of creatine supplementation (Figure 
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5), suggesting that creatine acts as a compatible osmolyte in the heart and other major organs 
(i.e., low LV weight is due to reduced water content). 
 
3.7 Creatine-naïve mice have smaller LV chamber volumes 
WT and creatine-naïve AGAT-/- mice underwent cine-MRI to assess global structure and function 
in vivo (Supplementary Figure). The difference in LV size is clearly evident in the representative 
mid-ventricular short-axis images and is reflected in the low LV mass and small ventricular end-
diastolic and end-systolic volumes in creatine-naïve AGAT-/- mice. We observed a significant 
reduction in cardiac output driven by trends in both heart rate and stroke volume, but with 
preserved ejection fraction. The physiological significance is open to interpretation given the large 
differences in body weight and composition. We therefore performed LV haemodynamic 
measurements, which are independent of chamber size.  
 
3.8 Creatine-naïve hearts exhibit haemodynamic impairment  
Compared to WT controls, creatine-naïve AGAT-/- mice had a distinct haemodynamic phenotype 
consisting of lower LV systolic pressure with normal end-diastolic pressures and significantly 
impaired contractility and relaxation as shown by the reduced rates of pressure rise (dP/dtmax) and 
fall (dP/dtmin) (Figure 6A-D). Maximal heart rate and dP/dtmax in response to dobutamine infusion 
was also lower in AGAT-/- hearts, indicating an impaired contractile reserve (Figure 6E-F).  
 
i) Creatine rescue: In order to establish causality, we treated mice with 0.5% dietary creatine, 
either for 1 week or 7 weeks, to determine whether this would rescue the in vivo phenotype. WT 
control mice were included for each treatment group, but did not differ in any haemodynamic 
parameter and were therefore combined into a single WT control group (Supplementary Table 
S2). 
In AGAT-/- mice, creatine supplementation corrected myocardial creatine levels within one week 
(Figure 6G), normalised LV end-systolic pressure, and increased end-diastolic pressure (Figure 
6A-B). This may reflect the osmotic effect of acute creatine replacement to increase muscle tone, 
because there was no apparent effect on functional parameters. For example, correcting creatine 
levels had no effect on either the inotropic or lusitropic deficits, or on contractile reserve. 
ii) Homoarginine rescue: Since creatine supplementation of AGAT-/- mice did not fully rescue 
the cardiac phenotype and AGAT-/- mice were also characterized by low HA plasma levels, we 
included a further group where we supplemented with HA via drinking water. Plasma HA levels 
were low in AGAT-/- mice and were significantly elevated after 10 days of oral supplementation 
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(Figure 6H). Surprisingly, all inotropic and lusitropic parameters (i.e. dP/dtmax, dP/dtmin and 
response to dobutamine) were rescued by HA supplementation (Figure 6C-F). 
iii) Isolated perfused heart: The presence of cardiac dysfunction in creatine-naïve AGAT-/- mice 
was confirmed ex vivo in Langendorff-perfused hearts (Figure 7A-D), suggesting that dysfunction 
is an intrinsic property and not secondary to altered loading conditions or differences in whole-
body composition or metabolism.  
 
3.9 Homoarginine deficiency impairs cardiomyocyte function 
We sought to confirm the in vivo and ex vivo findings at the single cardiomyocyte level. For this 
we used WT and AGAT-/- mice that had been fed a creatine-supplemented diet throughout life, 
i.e. a pure HA-deficiency without the potentially confounding effects of low creatine on cellular 
osmolarity, haemodynamic loading and whole body metabolism. HA-deficient cardiomyocytes 
showed a modest reduction in fractional shortening with significantly reduced shortening and re-
lengthening velocities (Figure 7E-H), suggesting that low HA levels per se can impair 
cardiomyocyte function. This was not associated with changes in [Ca2+]i transient amplitude, the 
time constant of [Ca2+]i transient decay (tau), or intracellular diastolic calcium levels (Figure 7 I-
L). See Supplemental Table S3 for details of statistical analysis. 
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4. Discussion 
We used AGAT-/- mice to study, for the first time, the cardiac consequences of absolute creatine 
deficiency, i.e. in the absence of other compensatory phosphagens. Our results offer multiple 
novel insights into myocardial creatine efflux, creatine as a cellular osmolyte, biochemical 
divergence between cardiac and skeletal muscle creatine, cardiac homoarginine (HA)  and their 
impact on cardiac function. 
4.1 Myocardial creatine loss 
Withdrawal of dietary creatine in AGAT-/- mice allowed us to measure the rate of myocardial 
creatine efflux for the first time. Degradation of creatine and phosphocreatine to creatinine is a 
spontaneous, non-enzymatic and irreversible process. Creatinine is formed at a constant rate, 
diffusing into the blood before being filtered and excreted by the kidneys.2 Starting from WT levels, 
a decrease of ~2.7% per day in myocardial creatine content was calculated, which is in close 
agreement with earlier estimates of whole-body creatine loss of ~2% per day.27 Our experiments 
had to be terminated after three months of withdrawal due to excessive body weight loss, which 
triggered our humane end-point to prevent unnecessary animal suffering. Residual creatine was 
therefore present at the point of phenotyping and previous -GPA experiments suggest that 
cardiac function is only impacted when less than ~20-25 % creatine remains.10, 28 Nevertheless, 
final creatine levels were well below that observed in the failing heart without impacting on in vivo 
function or contractile reserve. This argues against a causative role for low creatine in driving 
contractile dysfunction. It should be noted that the effect of HA deficiency was not apparent in this 
experiment because we compared knockout groups with and without dietary creatine (i.e., both 
groups were HA deficient). 
4.2 Creatine as compatible osmolyte 
Weight loss or low body weight has been a universal finding in creatine deficiency studies, either 
due to β-GPA feeding or GAMT-/-, and creatine-naïve AGAT-/- mice are even more severely 
affected.22 Our study was performed using non-invasive MR relaxometry, which allowed us to 
examine the effects on body composition before and after creatine rescue in the same mice. Our 
results demonstrated that fat mass, lean mass, and total water were lower in AGAT-/- mice and 
was rescued by creatine supplementation. The robust increase in total water was most notable, 
occurring within one week of creatine supplementation, which strongly suggests that creatine acts 
as an osmolyte in the heart and other organs, such that replacing cellular creatine also replaces 
water. In line with this observation, we found elevated levels of the established osmolyte, taurine, 
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in AGAT-/- hearts, which could represent a partial compensation for the loss of creatine as an 
osmolyte. The converse was observed in mice with elevated myocardial creatine, in which taurine 
levels were negatively correlated with creatine, suggesting a degree of interchangeability, i.e. 
compatible osmolytes.29 This is supported by cell culture studies in which creatine was as effective 
as taurine in protecting cultured muscle cells following exposure to hypertonic media.30 Indeed, 
an osmotic effect of creatine is the most likely explanation for the complete normalization of organ 
weights within one week of creatine supplementation.  
4.3 Cardiac adaptations to low creatine levels 
Creatine-naïve mice were bred using heterozygous mating to restrict the effects on development. 
This implies that they may have received small amounts of creatine via the placenta and suckling, 
but our experiments were performed in adult mice aged >20 weeks in which the absence of 
creatine was verified by multiple methods. Postnatal compensatory adaptations have been 
described even for a relatively short β-GPA feeding period, among them mitochondrial 
proliferation31 and changes in myosin isoenzyme expression associated with ventricular 
hypertrophy,6 although these may represent off-target effects of β-GPA. We cannot completely 
rule out the development of adaptations in AGAT-/- hearts, although we did not observe changes 
in mitochondrial respiration or citrate synthase activity (a marker of mitochondrial volume), nor did 
we observe cardiac hypertrophy at a histological or molecular level. In CK-deficient mice, 
mitochondrial rearrangement was described to reduce diffusion distances for high-energy 
phosphates,32 but detailed analysis of GAMT-/- hearts failed to detect similar alterations of creatine 
deficiency.33  
Other obvious adaptations were absent, e.g. adenylate kinase (AK) represents an alternative 
phosphotransfer mechanism that is upregulated in CK-deficient mouse hearts34. We did not 
observe changes in AK activity in AGAT-/- mice, although a definitive answer would require 
measurements of AK flux. These findings are in agreement with the GAMT-/- model, where 
differential proteomic analysis did not reveal any potential adaptations.12 Most importantly, we can 
rule out the contribution of guanidinoacetate participation to the CK reaction as a compensatory 
mechanism for the GAMT-/- cardiac phenotype.  
4.4 Skeletal versus cardiac muscle phenotype 
In contrast to the heart, AGAT-/- mice have severe muscular dystrophy manifesting as skeletal 
muscle atrophy, abnormal mitochondria, and reduced grip strength, all of which were completely 
rescued by creatine supplementation.15 The fundamental difference appears to be that ATP is 
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maintained at normal levels in the heart, but was 46% lower in skeletal muscle.15 Unsurprisingly, 
this energetic deficit leads to the activation of AMPK, which we confirmed in skeletal muscle, but 
which was absent in cardiac muscle within the same animals. AMPK is an important energy 
sensor acting to switch off energy-demanding processes and activating energy-saving and 
production-related pathways,35 as demonstrated by multiple changes in metabolic gene 
expression observed in AGAT-/- skeletal muscle.36 One downstream consequence is the 
stimulation of mitochondrial biogenesis via the PGC1-α pathway, which resulted in an elevation 
of the citrate synthase activity by 70% in skeletal muscle,15 but we did not observe any changes 
in the heart. This demonstrates a major divergence in the biochemical consequences of creatine 
depletion in skeletal versus cardiac muscle, perhaps reflecting higher mitochondrial cell density 
and capacity for oxidative phosphorylation in cardiomyocytes,37 making them less reliant on the 
CK system to maintain ATP. That phosphocreatine levels are considerably higher in skeletal 
muscle,2 supports the view of a relatively CK-dependent tissue, whereas the heart is too important 
to fail and therefore displays greater metabolic redundancy. 
A comparison of the skeletal muscle phenotype with GAMT-/-, too, provides valuable insight. 
GAMT-/- mice do not have overt muscle weakness and can run just as far and as fast as WT 
controls.12 Guanidinoacetate (GA), the creatine precursor, has been shown to accumulate in both 
muscle types, where it can be phosphorylated by the CK reaction.11, 13 Apparently, this is sufficient 
to compensate for creatine deficiency in skeletal muscle, hence the severe phenotype when GA 
is absent in AGAT-/-. In contrast, both GAMT-/- and AGAT-/- hearts show impaired contractile 
reserve,11 but this reflects HA deficiency in AGAT-/-. As GAMT-/- mice are not HA deficient 18, it 
may be possible that GA accumulation accounts for the limited contractile reserve in this model, 
e.g. by inhibition of the Na+/K+ pump.14 
4.5 Myocardial creatine is unnecessary to support baseline cardiac function 
We did not observe any baseline dysfunction in creatine-naïve AGAT-/- mice by cine-MRI, and this 
is in broad agreement with the earlier analogue feeding studies in which baseline dysfunction was 
found to be either relatively mild (e.g.5-7) or completely absent (e.g.,8-10), with dysfunction 
becoming apparent or exacerbated at higher workloads. The GAMT-/- model, too, is in agreement 
with this general pattern, showing normal function by cine-MRI and only a small reduction in LV 
systolic pressure at baseline.11 Our findings in AGAT-/- mice do not include potentially confounding 
effects of β-GPA or guanidinoacetate accumulation and support the concept that a fully 
functioning CK system is not required to maintain baseline cardiac function. Furthermore, we 
show that low creatine on its own is insufficient to drive cardiac dysfunction.  
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It is a limitation that our model is a global knockout, however this is unavoidable, since AGAT is 
predominately expressed in the kidney but not in the normal heart,38 so a cardiac-specific AGAT-
/- would be uninformative since creatine and HA are both taken up from the circulation. This means 
our in vivo haemodynamic phenotype could be confounded by changes in body composition, 
loading conditions and whole-body metabolism. For example, reduced dP/dtmax in creatine-naïve 
mice may have resulted from reduced load rather than from altered contractility. However, the 
fact that cardiac dysfunction in the creatine-naïve knockout persists in the ex vivo perfused heart, 
where loading conditions and metabolic substrates are controlled, strongly argues against whole-
body confounders. Furthermore, we observed slower contraction and relaxation in isolated 
cardiomyocytes from HA–deficient (but creatine-replete) hearts. These experiments also 
eliminate differences in cellular osmolarity, and suggests that low HA levels per se may contribute 
to cardiac dysfunction. The magnitude of this effect is relatively modest and these changes were 
not explained by consonant changes in intracellular calcium. Our data does not rule out the 
potential for synergy when both HA and creatine levels are low. 
4.6 Homoarginine and cardiac function 
It is notable that low circulating HA has been identified as a novel risk factor for multiple cardio- 
and cerebrovascular diseases (reviewed in 21). For example, in a prospective study of patients 
undergoing coronary angioplasty, low serum HA was independently associated with a higher risk 
of all-cause and cardiovascular mortality,20 including stroke, sudden cardiac death, fatal 
myocardial infarction and heart failure, with a positive correlation between HA levels and ejection 
fraction.39 Collectively, these studies indicate that low plasma HA is a biomarker for cardiovascular 
disease risk, but the linking mechanism has yet to be identified. Notably, a causal relationship 
between HA deficiency and ischaemic stroke has been demonstrated in AGAT-/- mice, which 
developed larger cerebral injuries that were rescued by HA supplementation.18  
Our analogous findings provide the first evidence that low HA per se may contribute to impaired 
in vivo cardiac function, suggesting a potential role in the pathophysiology of heart disease. This 
is supported by our recent study demonstrating that HA supplementation in wild-type mice with 
ischaemic heart failure preserved contractile reserve.23 
Our current study may also shed light on why AGAT expression is up-regulated in the human 
failing heart.40 Local creatine biosynthesis has been postulated, but seems unlikely in the absence 
of commensurate GAMT expression. An alternative explanation is that compensatory HA 
biosynthesis may support contractile function. 
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Finally, our findings may also be of relevance to patients with AGAT deficiency syndrome. This 
rare genetic disorder typically manifests in childhood as skeletal muscle myopathy and 
developmental delay, which responds to early creatine supplementation.41 Cardiac involvement 
has not been examined in these patients, but if confirmed to be present, our study predicts that 
HA supplementation would be beneficial. 
4.7 Conclusions 
Our findings represent the strongest evidence to date that a fully functioning CK system is not 
required for maintaining normal baseline cardiac function, or for supporting contractile reserve. 
Indeed, in vivo cardiac dysfunction in AGAT-/- mice is principally driven by homoarginine 
deficiency rather than creatine deficiency. This suggests that low homoarginine is more than just 
a risk factor for cardiovascular disease, but may play an active role in its pathophysiology. 
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Figure Legends 
Figure 1 Schematic showing experimental study design. (A) Creatine withdrawal study: AGAT-/- 
mice were bred and weaned onto a diet containing 0.5% creatine (w/w), which was then 
switched to a standard creatine-free diet at 18 weeks of age in the experimental group. These 
animals received multiple MRI and 1H-MRS examinations before LV haemodynamics and tissue 
harvest at ~25 weeks of age. (B) Creatine-naïve mice and dietary rescue: WT and AGAT-/- mice 
were bred and weaned onto a standard creatine-free diet for the first 4-5 months of life. Mice 
were then either maintained on this creatine-free diet, switched to a creatine supplemented diet 
for either 1 or 7 weeks, or given 14mg/L of homoarginine for 10 days while maintaining a 
creatine-free diet. Wild-type controls were included for all dietary manipulations. 
 
Figure 2 Withdrawal of dietary creatine in AGAT-/- mice reduces body weight and LV mass without 
affecting haemodynamic function. (A) Myocardial creatine depletion was estimated at 2.7 ± 0.4 % 
of the free creatine pool per day using in vivo 1H-MRS. Data were fitted using a kinetic model of 
non-enzymatic degradation, according to the following equation: [Cr]t = [Cr]t=0 . e-kt. (B) 
Representative 1H-MRS spectra of the same mouse before and after creatine withdrawal. The 
creatine peak (arrow) seen at day 0 is not visible by day 83. (C) Body weight decreased rapidly 
after 70 days of creatine-free diet (n=6). (D) LV mass calculated by in vivo cine-MRI falls during 
dietary creatine withdrawal. LV haemodynamic parameters were measured at day 90 in AGAT-/- 
mice with and without dietary creatine withdrawal (n=6 /group) under resting baseline conditions 
and with IV infusion of dobutamine. There were no significant differences between groups for (E) 
heart rate, (F) LV end-systolic pressure, (G) the rate of pressure rise maximum (dP/dtmax) as a 
measure of contractility, or (H) the rate of pressure rise minimum (dP/dtmin) as a measure of 
relaxation. Comparison was made by two-way repeated measures ANOVA and data are 
represented as mean ± SD. 
 
Figure 3 Absence of phosphocreatine (PCr) in creatine-naïve AGAT knockout mice does not alter 
key metabolic parameters in the heart. Representative 31P-Magnetic Resonance spectra in 
Langendorff-perfused hearts. PCr was the most prominent peak in hearts from wild-type mice (A), 
but was completely absent in hearts from creatine-naïve AGAT-/- mice (B), where inorganic 
phosphate (Pi) was elevated, and there was no change in ATP (appears as 3 peaks representing 
the γ, α and β phosphoryl groups). Key energy homeostasis enzymes and mitochondrial function 
were not significantly different between wild-type (WT) and creatine-naïve AGAT-/- (KO) hearts. 
(C) Total creatine kinase (CK) activity and percentage isoenzyme distribution (D), where Mito is 
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mitochondrial CK and the various dimers of Muscle and Brain isoforms; (E) adenylate kinase (AK) 
activity (all n=10 WT, n=13 KO). (F) AMPK activation expressed as the ratio of phospho- to total 
AMPK protein expression was not altered in LV, but was significantly elevated in hind-limb skeletal 
muscle, n=5 per group. (G) Citrate synthase activity (n=10 WT, n=13 KO) and (H) mitochondrial 
respiration with glutamate (5mM), malate (2.5mM) and Na+-pyruvate (5mM) as substrates (n=7 
WT, n=8 KO). Values are mean ± SD 
 
Figure 4 Creatine-naïve AGAT-/- mice have low body weight and altered composition rescuable 
by dietary creatine. (A) Creatine-naïve KO mice had low body weight associated with reduced 
water, fat and lean mass (***P<0.001; n=14 male and 14 female per group). (B) These changes 
were not proportional because the linear relationship between % body fat and % total water was 
significantly altered in KO mice (P<0.0001 for slope). Dietary supplementation with 0.5% creatine 
for 1 week abolished the fat-water relationship, which was rescued to WT values after 7 weeks of 
dietary creatine and was unaltered by homoarginine (HA) supplementation (C). Values for body 
weight (D), fat mass (E), lean mass (F) and total water (G) in the same mice before and after 1-
week and 7-week creatine supplementation or 10-day homoarginine supplementation are shown 
in WT (open circles) and KO (triangles). Lean mass and total water were rapidly changing, 
suggesting an osmotic role for creatine, whereas fat mass only changed with chronic dietary 
creatine. Each data point represents mean ± SD for n=7-10 mice except HA wild-type (n=4), ** 
denotes P<0.01,***P<0.001, **** P<0.0001 compared to pre-treatment values. 
 
Figure 5 Creatine-naïve AGAT-/- mice have low vital organ weights that are rapidly rescued by 
dietary creatine supplementation. Post-mortem blotted organ weights from left ventricle (A), lung 
(B), liver (C) and kidney (D) taken from wild-type (WT, n=29), creatine-naïve knockout (KO, n=10), 
and KO mice supplemented with 0.5% dietary creatine for 1 week (n=7), 7 weeks (n=9), or 
homoarginine (HA) 14mg/L added to the drinking water (n=7). Data are represented as mean ± 
SD, ** denotes P<0.01 and ** P<0.001 compared to WT and ## P<0.01, ### P<0.001 compared 
to creatine-naïve knockout. 
 
Figure 6 In vivo haemodynamic measurements in Creatine-naïve AGAT-/- (KO) mice shows 
inotropic and lusitropic deficits rescued by homoarginine but not by creatine supplementation. (A) 
LV end-systolic pressure, (B) LV end-diastolic pressure, (C) the rate of pressure rise maximum 
(dP/dtmax) as a measure of contractility, (D) the rate of pressure rise minimum (dP/dtmin) as a 
measure of relaxation. (E) and (F) are heart rate and dP/dtmax respectively during IV infusion with 
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dobutamine at 16ng/g BW/min. WT control and treatment groups did not significantly differ for any 
of the parameters and were subsumed into one group (n=29), all other groups n=7-10. (G) 
Supplementation with 0.5% dietary creatine for 1 week normalised myocardial creatine levels 
(n=7-8). (H) Plasma levels of homoarginine were significantly lower in KO (n=6) versus WT (n=6) 
and are elevated by supplementation via drinking water (n=3). All data are represented as mean 
± SD, * denotes P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared to WT and #P<0.05, 
## P<0.01, ### P<0.001, #### P<0.0001 compared to creatine-naïve knockout. 
 
Figure 7 Contractile dysfunction is confirmed ex vivo in creatine-naïve hearts and a role for 
homoarginine-deficiency is confirmed in creatine-replete isolated cardiomyocytes. Hearts 
perfused in Langendorff mode from wild-type (WT; n=7) and creatine naïve AGAT-/- mice (KO; 
n=8) showing (A) Left ventricular end-systolic pressure, (B) LV developed pressure, (C) Heart 
rate, (D) Rate pressure product. Mean values ± SD with * denoting P<0.05 by two-way unpaired 
t-test. Cardiomyocytes were isolated from WT and AGAT-/- mice supplemented with 0.5% dietary 
creatine (i.e. homoarginine deficiency only). (E) Averaged cell shortening recording in field-
stimulated (3 Hz, 35 °C) LV myocytes. (F) AGAT-/- cardiomyocytes show a trend for impaired 
fractional shortening and (G,H) slower shortening and re-lengthening kinetics compared to WT 
cardiomyocytes (n=106/97 cells from 7 hearts per genotype). This occurred in the absence of 
differences in [Ca2+]i transient amplitude (I,J) the decay constant of the [Ca2+]i transient (tau) (K) 
or in diastolic Ca2+ levels (L) (n=51/53 cells from 6/6 hearts per genotype). Data are represented 
as median (IQR), P values were calculated by hierarchical statistical analysis on normally 
distributed data or on logarithmic transformed data (as indicated in Supplementary Table S3). 
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Table: Metabolites and markers of hypertrophy in WT and AGAT-/- creatine-naïve hearts 
 Wild-type AGAT-/- 
Cr-naïve 
31P-MRS (n=6) (n=4) 
   PCr (mM) 12.7 ± 2.3 0 
   ATP (mM) 7.0 ± 0.4 6.9 ± 0.8 
   Pi (mM) 1.5 ± 0.5 4.1 ± 1.8* 
   pHi 6.9 ± 0.1 7.0 ± 0.1 
HPLC (n=5) (n=5) 
  Total creatine (nmol/mg protein)   68 ± 5 <12 ± 1 
  Total adenine nucleotides (nmol/mg protein) 38 ± 11 42 ± 3 
Solution state 1H-NMR  (n=3) (n=3) 
   Creatine (normalized intensity) 92.0 ± 1.1 1.5 ± 0.6**** 
   Taurine (normalized intensity) 0.17 ± 0.02 0.21 ± 0.01* 
Post-mortem weights (5M/5F) (5M/5F) 
    Body weight (g) 28.1 ± 6.1 13.4 ± 2.0*** 
    Tibia length (mm) 17.9 ± 0.6 17.1 ± 0.3** 
    LV weight (mg) 83 ± 14 61 ± 4*** 
    LV/BWt (mg/g) 2.98 ± 0.28 4.62 ± 0.49*** 
    LV/tibial length (mg/mm) 4.59 ± 0.71 3.56 ± 0.23*** 
    RV weight (mg) 23.5 ± 4.6 15.1 ± 1.7*** 
Hypertrophic markers (n=9) (n=10) 
     ANP mRNA (% WT) 100 ± 42 420 ± 198*** 
     BNP mRNA (% WT) 100 ± 28 134 ± 87 
     -MHC mRNA (% WT) 100 ± 28 260 ± 335 
     -SA mRNA (% WT) 100 ± 57 36 ± 19** 
Histology (n=3) (n=3) 
     Myocyte cross-sectional area (µm2) 198 ± 11 210 ± 70 
LV is left ventricle; RV, right ventricle, ANP, atrial natriuretic peptide; BNP, brain natriuretic 
peptide; β-MHC, beta myosin heavy chain; α-SA, alpha skeletal actin. Values are 
represented as mean ± SD. * denotes P<0.05, ** P<0.01, *** P<0.001 and **** p<0.0001 vs 
WT.  
 
Table(s)
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